As GLP-1 receptor agonists continue to surge in popularity for weight management and diabetes treatment, market data and recent reporting indicate a rising trend among younger adults, with anecdotal reports pointing to increased usage on college campuses. According to market research cited by Fox News Digital, medications including semaglutide—marketed as Ozempic and Wegovy—and tirzepatide—marketed as Mounjaro and Zepbound—are experiencing their fastest growth rates among individuals under the age of 40, particularly young women.
JAMA Data and Campus Surveys Track Youth Prescription Trends
A 2024 analysis published in JAMA documented that 162,439 young adults between the ages of 18 and 25 received at least one dispensed GLP-1 prescription in 2023. Women accounted for 76.4% of those patients, though the analysis encompassed medications prescribed for both diabetes management and weight loss. Separately, the 2025 Monitoring the Future survey reported that 2% of surveyed students in grades 8, 10, and 12 indicated using a prescription GLP-1 medication, while another 2% reported using one without a prescription.
The trend has drawn broader public attention following a recent feature in The Cut titled “The Secret ‘Ozempidemic’ on Sorority Row.” The article reports that GLP-1 weight-loss drugs have integrated into campus culture at select elite universities, particularly during competitive sorority recruitment processes. Three female students interviewed under pseudonyms told the publication they used compounded semaglutide or tirzepatide to enhance their prospects during rush events and to conform to an increasingly thin beauty standard.
Interviews and Expert Perspectives on Social Pressures
Students interviewed for the feature highlighted social media pressures and peer weight-loss competitions as drivers for increased utilization. “For many young women who have just arrived on campus, thinness feels like the ticket into the best possible college experience,” one student stated. A former sorority recruiter added that the availability of the drugs has fostered a perception that rapid weight loss is easily attainable.
Jay Campbell, a longevity and peptide expert and author, told Fox News Digital that while these medications serve as vital interventions for individuals experiencing metabolic dysregulation, they are increasingly utilized by younger demographics as aesthetic shortcuts. “For someone who’s metabolically dysregulated, they are a genuine medical intervention,” Campbell said. “But to a 20-year-old sorority member with a normal BMI, they look like an aesthetic hack in a syringe.” Campbell noted that high body-image sensitivity among college-aged women is amplified by social visibility and platforms like Instagram.
Pro Tips: Considerations for College Students
For college students evaluating weight-loss treatments, peptide expert Jay Campbell outlines five key considerations:
- Assess whether the medication is medically appropriate for a diagnosed condition rather than cosmetic goals.
- Protect muscle mass through adequate protein intake and resistance training during weight loss.
- Understand fertility and contraceptive considerations, as tirzepatide can reduce the effectiveness of oral hormonal contraceptives during initiation and dose increases, and semaglutide labeling advises stopping Wegovy at least two months prior to a planned pregnancy.
- Monitor mental health and discuss any mood symptoms, depression, anxiety, or history of eating disorders with a prescriber.
- Recognize the limitations of long-term data for individuals starting treatment at a normal body weight.
Frequently Asked Questions
What do recent studies show about GLP-1 use in young adults?
A 2024 JAMA analysis found that 162,439 young adults aged 18 to 25 received at least one dispensed GLP-1 prescription in 2023, with women accounting for 76.4% of patients. Additionally, the 2025 Monitoring the Future survey reported that 2% of students in grades 8, 10, and 12 used a prescription GLP-1, and 2% reported using one without a prescription.
Why are GLP-1 medications reportedly being used during sorority recruitment?
According to reporting in The Cut and commentary from experts like Jay Campbell, some college students utilize compounded semaglutide or tirzepatide to meet competitive beauty ideals and social visibility demands during sorority rush processes.
What are the medical considerations regarding fertility and GLP-1 use?
Experts emphasize that GLP-1 drugs should not be used during pregnancy. Semaglutide labeling advises discontinuing Wegovy at least two months before a planned pregnancy, and the FDA notes that tirzepatide can reduce oral contraceptive efficacy during initial treatment and dose escalation phases.
What are your thoughts on the rising trend of GLP-1 use among younger demographics? Share your perspective in the comments below, or subscribe to our health newsletter for ongoing updates.
Related reading